23
Apr
Apr
Oral Obesity Drug Breakthrough: Eli Lilly Soars 16% as Novo Nordisk Plunges 7% in Market Shakeup
-
News Editor / 4 months
- 0
- 1 min read
The 100 billion obesity treatment market witnessed a seismic shift Thursday as Eli Lilly′s positive Phase 3 trial results for its oral GLP−1 drug orforglipron triggered a dramatic 728 billion evaporate from its market capitalization in a single trading session. Trial Results That Changed the Game: Orforglipron demonstrated 14.7% average weight loss vs placebo in […]